On 3 December 2018, GlaxoSmithKline (GSK) announced that it will be acquiring Tesaro...
- Is China the next great hope for the pharma industry?
- Mallinckrodt to spin off its speciality generics business next year
- Brexit looms over UK’s attractiveness as a research destination
- Uncertainty drives negative Brexit sentiment in healthcare
- Industry experts believe External Reference Pricing is coming to the US
The clinical trial landscape for GSK’s latest acquisition Tesaro
On 3 December 2018, GlaxoSmithKline (GSK) announced that it will be acquiring Tesaro to bolster its drug development portfolio, especially in oncology. With the help of GlobalData’s Pharma Intelligence Center database, a look at Tesaro’s clinical trial landscape can provide an analysis of potential R&D plans.
Biopharmaceuticals and Liposomal Formulations
Polymun offers the development of liposomal formulations for all kinds of pharmaceutically active ingredients and vaccine antigens. A broad spectrum of analytical methods has been established for this purpose.
Allergan’s Phase III Botox trial for depression pushed to H2 2019
Allergan’s Botox (onabotulinumtoxin A) Phase III trial in major depressive disorder (MDD) is slated to initiate in the second half of 2019 (2H19), said a company spokesperson.
Foamix’s rosacea drug FMX103 splits views on sunburn risk
Foamix Pharmaceuticals’ FMX103 (1.5% topical minocycline foam) has experts split over the drug’s real-world ability to protect against sunburn, despite expected FDA approval for moderate-to-severe facial papulopustular rosacea.
Is China the next great hope for the pharma industry?
Many top pharma firms have been forced to drop prices to get a slice of the Chinese market, but that hasn’t dampened spirits one bit – on the contrary, CEOs from companies like AstraZeneca and Pfizer have been celebrating dramatic Chinese sales increases in 2018. So how is China’s pharmaceutical market growing and is it really a clean bill of health for any internationals lining up to profit?
Mallinckrodt to spin off its speciality generics business next year
After two years of planning, UK-based pharmaceutical company Mallinckrodt has announced plans to split its speciality generics and active pharmaceutical ingredients (APIs) business, in addition to the drug amitiza (lubiprostone), from its speciality pharmaceutical brands segment.
Are you a manufacturer, importer, distributor or wholesaler of healthcare products? RAQAC has the specialised knowledge to help you navigate the Canadian regulatory requirements for registering and marketing products.
Distek Model 2500 Dissolution System
The Distek Model 2500 dissolution system offers great flexibility and configurability. It
can be configured as US Pharmacopoeia (USP) Apparatus 1, 2, 5 and 6 plus intrinsic dissolution.
Label expansion is a common strategy in Non-Hodgkin’s Lymphoma
An overarching strategy in Non-Hodgkin’s Lymphoma (NHL) research and development, both in the past and current landscape, has been for companies to explore commercialisation across multiple NHL subtypes and lines of therapy in order to capture the broadest possible patient share and maximise revenue.
The bioterrorism threat: what power can terrorists wield with microbes?
Infectious diseases kill over 17 million people yearly and the agents that cause them are toxic, widespread and reproducible. These factors make biological organisms a potential weapon for terrorists.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.